Protective effects of panax notoginseng saponins on cardiovascular diseases: A comprehensive overview of experimental studies

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Yang, Xiaochen ^a   Xiong, Xingjiang ^a   Wang, Heran ^b   Wang, Jie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GINSENOSIDE R1; GINSENOSIDE RB 1; GINSENOSIDE RG 1; PANAX NOTOGINSENG SAPONIN; SAPONIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTICOAGULATION; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERLIPIDEMIA; HYPERPLASIA; HYPOXIA; INFLAMMATION; INTIMAL HYPERPLASIA; LEFT VENTRICULAR REMODELING; NONHUMAN; PANAX NOTOGINSENG; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASODILATATION;

EID: 84923114076     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/204840     Document Type: Review

References (83)

1. P. Chan, G. N. Tomas, and B. Tomlinson, "Protective efects of trilinolein extracted from Panax notoginseng against cardiovascular disease," Acta Pharmacologica Sinica, vol. 23, no. 12, pp. 1157-1162, 2002.
2. T. T. X. Dong, X. M. Cui, Z. H. Song et al., "Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents," Journal of Agricultural and Food Chemistry, vol. 51, no. 16, pp. 4617-4623, 2003.
3. Y. Yao, W. Y. Wu, S. H. Guan et al., "Proteomic analysis of diferential protein expression in rat platelets treated with notoginsengnosides," Phytomedicine, vol. 15, no. 10, pp. 800-807, 2008.
4. C. Ying, "Pharmacodynamical research and clinical application of Panax pseudo-ginseng saponins," Guangxi Medical Journal, vol. 20, no. 6, pp. 1109-1112, 1998.
5. L.-M. Yu, Y.-K. Deng, F. Yuan et al., "The research progress of Panax notoginseng saponins against myocardial ischemia," China Pharmacist, vol. 14, no. 11, pp. 1685-1687, 2011.
6. L. W. T. Cheung, K. W. Leung, C. K. C. Wong, R. N. S. Wong, and A. S. T. Wong, "Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fbroblast growth factor receptor-1," Cardiovascular Research, vol. 89, no. 2, pp. 419-425, 2011.
7. K. W. Leung, H. M. Ng, M. K. S. Tang, C. C. K. Wong, R. N. S. Wong, and A. S. T. Wong, "Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1c to promote angiogenesis," Angiogenesis, vol. 14, no. 4, pp. 515-522, 2011.
8. Z.-T. Wang, L.-H. Han, M.-J. Zhu et al., "Efects of Chinese traditional medicines on angiogenesis and correlative growth factor expression in the ischemic myocardium of the rats with myocardial infarction," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 4, no. 4, pp. 305-307, 2006.
9. The Collaborative Study Group on Trends of Cardiovascular Diseases in China and Prevention, "Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades," Chinese Journal of Cardiology, vol. 29, pp. 74-79, 2001.
10. C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth, "Platelet-active drugs: the relationships among dose, efectiveness, and side efects," Chest, vol. 126, no. 3, supplement, pp. 234S-264S, 2004.
11. A. J. Lau, D. F. Toh, T. K. Chua, Y. K. Pang, S. O. Woo, and H. L. Koh, "Antiplatelet and anticoagulant efects of Panax notoginseng: comparison of raw and steamed Panax notogin-seng with Panax ginseng and Panax quinquefolium," Journal of Ethnopharmacology, vol. 125, no. 3, pp. 380-386, 2009.
12. W. J. Zhang, J. Wojta, and B. R. Binder, "Efect of notoginseno-side R1 on the synthesis of components of the fbrinolytic system in cultured smooth muscle cells of human pulmonary artery," Cellular and Molecular Biology, vol. 43, no. 4, pp. 581-587, 1997.
13. S. Chen, J. Liu, X. Liu et al., "Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes," Journal of Ethnopharmacology, vol. 137, no. 1, pp. 263-270, 2011.
14. E. Palojoki, A. Saraste, A. Eriksson et al., "Cardiomyocyte apoptosis and ventricular remodeling afer myocardial infarction in rats," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 280, no. 6, pp. H2726-H2731, 2001.
15. A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, and L. Voipio-Pulkki, "Apoptosis in human acute myocardial infarction," Circulation, vol. 95, no. 2, pp. 320-323, 1997.
16. F. J. Giordano, "Oxygen, oxidative stress, hypoxia, and heart failure," Journal of Clinical Investigation, vol. 115, no. 3, pp. 500-508, 2005.
17. Z. Q. Zhao, J. S. Corvera, M. E. Halkos et al., "Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579-H588, 2003.
18. H. Kin, Z. Q. Zhao, H. Y. Sun et al., "Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion," Cardiovascular Research, vol. 62, no. 1, pp. 74-85, 2004.
19. M. Fujita, H. Asanuma, A. Hirata et al., "Prolonged transient acidosis during early reperfusion contributes to the cardiopro-tective efects of postconditioning," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 292, no. 4, pp. H2004-H2008, 2007.
20. M. Crompton, S. Virji, V. Doyle, N. Johnson, and J. M. Ward, "The mitochondrial permeability transition pore," Biochemical Society Symposium, vol. 66, pp. 167-179, 1999.
21. S. M. Davidson, D. Hausenloy, M. R. Duchen, and D. M. Yellon, "Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection," International Journal of Biochemistry and Cell Biology, vol. 38, no. 3, pp. 414-419, 2006.
22. D. J. Hausenloy, A. Tsang, and D. M. Yellon, "The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning," Tre nd s in Cardiovascular Medicine, vol. 15, no. 2, pp. 69-75, 2005.
23. S. C. Chen, J. J. Cheng, M. H. Hsieh et al., "Molecular mechanism of the inhibitory efect of trilinolein on endothelin-1-induced hypertrophy of cultured neonatal rat cardiomyocytes," Planta Medica, vol. 71, no. 6, pp. 525-529, 2005.
24. R. Shi, L. Liu, Y. Huo, and Y. Y. Cheng, "Study on protective efects of Panax notoginseng saponins on doxorubicin-induced myocardial damage," China Journal of Chinese Materia Medica, vol. 32, no. 24, pp. 2632-2635, 2007.
25. J. Q. Chen, Y. G. Zhang, S. L. Li, Q. Zeng, and M. Z. Rong, "Efects of Panax notoginseng saponins on myocardial adenosinetriphosphatase," Acta Pharmacologica Sinica, vol. 15, no. 4, pp. 347-350, 1994.
26. D. M. Cosgrove, F. D. Loop, B. W. Lytle et al., "Predictors of reoperation afer myocardial revascularization," Journal of Toracic and Cardiovascular Surgery, vol. 92, no. 5, pp. 811-821, 1986.
27. O. H. Frazier, D. A. Cooley, K. A. Kadipasaoglu et al., "Myocardial revascularization with laser: preliminary fndings," Circulation, vol. 92, no. 9, supplement, pp. II58-II65, 1995.
28. S. Banai, M. T. Jaklitsch, M. Shou et al., "Angiogenic-induced enhancement of collateral blood fow to ischemic myocardium by vascular endothelial growth factor in dogs," Circulation, vol. 89, no. 5, pp. 2183-2189, 1994.
29. A. Yanagisawa-Miwa, Y. Uchida, F. Nakamura et al., "Salvage of infarcted myocardium by angiogenic action of basic fbroblast growth factor," Science, vol. 257, no. 5075, pp. 1401-1403, 1992.
30. E. F. Unger, S. Banai, M. Shou et al., "Basic fbroblast growth factor enhances myocardial collateral fow in a canine model," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 266, no. 4, pp. H1588-H1595, 1994.
31. C. J. Magovern, C. A. Mack, J. Zhang, T. K. Rosengart, O. W. Isom, and R. G. Crystal, "Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor," Human Gene Terapy, vol. 8, no. 2, pp. 215-227, 1997.
32. M. Shou, V. Tirumurti, M. A. S. Rajanayagam et al., "Efect of basic fbroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels," Journal of the American College of Cardiology, vol. 29, no. 5, pp. 1102-1106, 1997.
33. R. C. Chiu, A. Zibaitis, and R. L. Kao, "Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation," Annals of Toracic Surgery, vol. 60, no. 1, pp. 12-18, 1995.
34. Y. Lei, W. Tian, L. Q. Zhu, J. Yang, and K. J. Chen, "Efects of Radix Ginseng and Radix Notoginseng formula on secretion of vascular endothelial growth factor and expression of vascular endothelial growth factor receptor-2 in human umbilical vein endothelial cells," Journal of Chinese Integrative Medicine, vol. 8, no. 4, pp. 368-372, 2010.
35. World Health Organization and Department of Health Statistics and Informatics in the Information, Evidence and Research Cluster, The Global Burden of Disease 2004 Update, WHO, Geneva, Switzerland, 2004.
36. P. Davidson, K. Hancock, D. Leung et al., "Traditional Chinese Medicine and heart disease: what does Western medicine and nursing science know about it?" European Journal of Cardiovascular Nursing, vol. 2, no. 3, pp. 171-181, 2003.
37. S. Y. Han, H. X. Li, X. Ma et al., "Evaluation of the anti-myocardial ischemia efect of individual and combined extracts of Panax notoginseng and Carthamus tinctorius in rats," Journal of Ethnopharmacology, vol. 145, no. 3, pp. 722-727, 2013.
38. D. Zhu, L. Wu, C. R. Li et al., "Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis," Journal of Cellular Biochemistry, vol. 108, no. 1, pp. 117-124, 2009.
39. Scandinavian Simvastatin Survival Study Group, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)," The Lancet, vol. 344, no. 8934, pp. 1383-1389, 1994.
40. F. M. Sacks, M. A. Pfefer, L. A. Moye et al., "The efect of pravastatin on coronary events afer myocardial infarction in patients with average cholesterol levels," The New England Journal of Medicine, vol. 335, no. 14, pp. 1001-1009, 1996.
41. P. S. Sever, B. Dahlöf, N. R. Poulter et al., "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial," The Lancet, vol. 361, no. 9364, pp. 1149-1158, 2003.
42. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels," The New England Journal of Medicine, vol. 339, no. 19, pp. 1349-1357, 1998.
43. Heart Protection Study Collaborative Group, "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial," The Lancet, vol. 360, no. 9326, pp. 7-22, 2002.
44. A. S. Brown, R. G. Bakker-Arkema, L. Yellen et al., "Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fuvastatin, lovastatin and simvastatin," Journal of the American College of Cardiology, vol. 32, no. 3, pp. 665-672, 1998.
45. W. Xia, C. Sun, Y. Zhao, and L. Wu, "Hypolipidemic and antioxidant activities of Sanchi (Radix Notoginseng) in rats fed with a high fat diet," Phytomedicine, vol. 18, no. 6, pp. 516-520, 2011.
46. A. Rhule, B. Rase, J. R. Smith, and D. M. Shepherd, "Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng," Journal of Ethnopharmacol-ogy, vol. 116, no. 1, pp. 179-186, 2008.
47. L. Wu, W. Zhang, Y. H. Tang et al., "Efect of total saponins of "panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats," Phytomedicine, vol. 17, no. 3-4, pp. 233-240, 2010.
48. J. Wang, L. Wu, W. Zhang, and C. Deng, "Efect of Panax notoginseng saponins on vascular intima hyperplasia and PCNA expression in rat aorta afer balloon angioplasty," China Journal of Chinese Materia Medica, vol. 34, no. 6, pp. 735-739, 2009.
49. W. Zhang, G. Chen, and C. Q. Deng, "Efects and mechanisms of total Panax notoginseng saponins on proliferation of vascular smooth muscle cells with plasma pharmacology method," Journal of Pharmacy and Pharmacology, vol. 64, no. 1, pp. 139-145, 2012.
50. L. Xu, J. T. Liu, N. Liu, P. P. Lu, and X. M. Pang, "Efects of Panax notoginseng saponins on proliferation and apoptosis of vascular smooth muscle cells," Journal of Ethnopharmacology, vol. 137, no. 1, pp. 226-230, 2011.
51. S. G. Lin, X. L. Zheng, Q. Y. Chen, and J. J. Sun, "Efect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum," Acta Pharmacologica Sinica, vol. 14, no. 4, pp. 314-316, 1993.
52. J. Wang and J. H. Hu, "Inhibitory efect of Panax notoginseng on the VSMC proliferation induced by hyperlipidemia serum," China Journal of Chinese Materia Medica, vol. 31, no. 7, pp. 588-590, 2006.
53. G. Liu, B. Wang, J. Zhang, H. Jiang, and F. Liu, "Total panax notoginsenosides prevent atherosclerosis in apolipoprotein E-knockout mice: role of downregulation of CD40 and MMP-9 expression," Journal of Ethnopharmacology, vol. 126, no. 2, pp. 350-354, 2009.
54. J. H. Qin, L. Q. Zhu, and W. Cui, "Efects of panax notoginseng saponins on expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells injury induced by oxidized low-density lipoprotein," Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 12, pp. 1096-1099, 2008.
55. Y. Liu, H. G. Zhang, Y. Jia, and X. H. Li, "Panax notoginseng saponins attenuate atherogenesis accelerated by zymosan in rabbits," Biological and Pharmaceutical Bulletin, vol. 33, no. 8, pp. 1324-1330, 2010.
56. J. S. Fan, D. N. Liu, G. Huang et al., "Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and infammation by inducing liver X receptor alpha expression," Journal of Ethnopharmacology, vol. 142, no. 3, pp. 732-738, 2012.
57. Y. G. Zhang, H. G. Zhang, G. Y. Zhang et al., "Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profle and an anti-infammatory action," Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 10, pp. 1238-1244, 2008.
58. Z. Yuan, Y. Liao, G. Tian et al., "Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-cB translocation," Journal of Ethnopharmacology, vol. 138, no. 1, pp. 150-155, 2011.
59. N. Wang, J. B. Wan, S. W. Chan et al., "Comparative study on saponin fractions from Panax notoginseng inhibiting infammation-induced endothelial adhesion molecule expression and monocyte adhesion," Chinese Medicine, vol. 6, article 37, 2011.
60. S. J. Hong, J. B. Wan, Y. Zhang et al., "Angiogenic efect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafsh in vivo," Phytotherapy Research, vol. 23, no. 5, pp. 677-686, 2009.
61. S. R. Ommen, J. A. Odell, and M. S. Stanton, "Atrial arrhythmias afer cardiothoracic surgery," The New England Journal of Medicine, vol. 336, no. 20, pp. 1429-1434, 1997.
62. M. H. Kim, G. M. Deeb, F. Morady et al., "Efect of postoperative atrial fbrillation on length of stay afer cardiac surgery (the postoperative atrial fbrillation in cardiac surgery study [PACS2])," The American Journal of Cardiology, vol. 87, no. 7, pp. 881-885, 2001.
63. W. Wu, X.M. Zhang, P.M. Liu, J.M. Li, and J.F. Wang, "Efectsof Panax notoginseng saponin Rg1 on cardiac electrophysiological properties and ventricular fbrillation threshold in dogs," Acta Pharmacologica Sinica, vol. 16, no. 5, pp. 459-463, 1995.
64. D. A. Calhoun, D. Jones, S. Textor et al., "Resistant hypertension: siagnosis, evaluation, and treatment a scientifc statement from the American heart association professional education committee of the council for high blood pressure research," Hypertension, vol. 51, no. 6, pp. 1403-1419, 2008.
65. C. Y. Kwan and T. K. Kwan, "Efects of Panax notoginseng saponins on vascular endothelial cells in vitro," Acta Pharma-cologica Sinica, vol. 21, no. 12, pp. 1101-1105, 2000.
66. 2+ channels in vascular smooth muscle cells," European Journal of Pharmacology, vol. 548, no. 1-3, pp. 129-136, 2006.
67. S. Y. Li, X. G. Wang, M. M. Ma et al., "Ginsenoside-Rd potentiates apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells through the mitochondrial pathway," Apoptosis, vol. 17, no. 2, pp. 113-120, 2012.
68. C. Pan, Y. Huo, X. An et al., "Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation," Vascular Pharmacology, vol. 56, no. 3-4, pp. 150-158, 2012.
69. H. Shemirani, R. Hemmati, A. Khosravi, M. Gharipour, and M. Jozan, "Echocardiographic assessment of inappropriate lef ventricular mass and lef ventricular hypertrophy in patients with diastolic dysfunction," Journal of Research in Medical Sciences, vol. 17, no. 2, pp. 133-137, 2012.
70. T. A. Manolio, D. Levy, R. J. Garrison, W. P. Castelli, and W. B. Kannel, "Relation of alcohol intake to lef ventricular mass: the Framingham study," Journal of the American College of Cardiology, vol. 17, no. 3, pp. 717-721, 1991.
71. Y. Zhou, L. Tian, and K. Mo, "Relationship between the inhibitory efects of PNS on cardiac hypertrophy and its action on neurohormonal factor," China Journal of Chinese Materia Medica, vol. 30, no. 12, pp. 916-919, 2005.
72. 2+ and activity of calcium pump of membrane of sarcoplasmic reticulum in SHR," China Journal of Chinese Materia Medica, vol. 23, no. 3, pp. 173-175, 1998.
73. J. W. Guo, L. M. Li, G. Q. Qiu et al., "Efects of Panax notoginseng saponins on ACE2 and TNF-alpha in rats with post-myocardial infarction-ventricular remodeling," Journal of Chinese Medicinal Materials, vol. 33, no. 1, pp. 89-92, 2010.
74. K. Richard, "Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey," Drug Design, Development and Terapy, vol. 5, pp. 325-380, 2011.
75. W. Rosamond, K. Flegal, K. Furie et al., "Heart disease and stroke statistics-2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee," Circulation, vol. 117, no. 4, pp. e25-146, 2008.
76. E. D. Grech, "ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure," The British Medical Journal, vol. 326, no. 7399, pp. 1137-1140, 2003.
77. D. Lloyd-Jones, R. J. Adams, T. M. Brown et al., "Executive summary: heart disease and stroke statistics-2010 update: a report from the American heart association," Circulation, vol. 121, no. 7, pp. 948-954, 2010.
78. X. J. Xiong, X. C. Yang, Y. M. Liu, Y. Zhang, P. Q. Wang, and J. Wang, "Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science," Hypertension Research, vol. 36, no. 7, pp. 570-579, 2013.
79. X. J. Xiong, X. C. Yang, W. Liu, F. Y. Chu, P. Q. Wang, and J. Wang, "Trends in the treatment of hypertension from the perspective of traditional chinese medicine," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 275279, 13 pages, 2013.
80. J. Wang, X. J. Xiong, G. Y. Yang et al., "Chinese herbal medicine Qi Ju di Huang Wan for the treatment of essential hypertension: a systematic review of randomized controlled trials," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 262685, 10 pages, 2013.
81. J. Wang and X. J. Xiong, "Current situation and perspectives of clinical study in integrative medicine in China," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 268542, 11 pages, 2012.
82. J. Wang, K. W. Yao, X. C. Yang et al., "Chinese patent medicine Liu Wei di HuangWan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714805, 7 pages, 2012.
83. S. Aziz, J. L. Morris, and R. A. Perry, "Late stent thrombosis associated with coronary aneurysm formation afer sirolimus-eluting stent implantation," Journal of Invasive Cardiology, vol. 19, no. 4, pp. E96-E98, 2007.